Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
You may also be interested in...
The company reported positive topline data for the drug in ulcerative colitis, but analysts noted caveats about its earliness as well as lackluster performance to date by others in the S1P class.
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.